May 20, 2022 |
IMPEL PHARMACEUTICALS INC.
201 Elliot Avenue West, Suite 260
Seattle, WA 98119
May 20, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Margaret Schwartz | |
| Re: | Impel Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-264987) filed May 16, 2022. | |
Requested Date: May 24, 2022
Requested Time: 4:00 PM Eastern Time
Ladies and Gentlemen:
Impel Pharmaceuticals Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.
The Registrant hereby authorizes Amanda L. Rose and Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553 or, in her absence, to Mr. Mitteness at (206) 389-4533.
* * *
| Sincerely, | ||
| IMPEL PHARMACEUTICALS INC. | ||
| By: | /s/ Adrian Adams | |
| Adrian Adams | ||
| Chief Executive Officer | ||
| Cc | Adrian Adams, Chief Executive Officer |
John Leaman, M.D., Chief Financial & Business Officer
Impel Pharmaceuticals Inc.
Amanda Rose, Esq.
Alan Smith, Esq.
Ryan Mitteness, Esq.
Fenwick & West LLP
[Signature Page to Company Acceleration Request Letter]
